Skip to main content
. 2017 Jun 28;8(44):76116–76128. doi: 10.18632/oncotarget.18814

Figure 4. IL-6 mediated the effect of CAFs on migration and EMT in lung cancer cells.

Figure 4

(A) CAF-CM, NF-CM and lung cancer cell lines cultured medium were collected. The IL-6 levels were quantified by ELISA. (B) The mRNA expression of IL-6 in CAFs, NFs and lung cancer cell lines were detected by qPCR. (C) Lung cancer cells were treated with DMEM, CAF-CM, CAF-CM + IL-6 neutralizing antibody (5 μg/ml) or DMEM + IL-6 (200 ng/ml) for 24 to 48 h. Cell migration ability was measured by wound healing assays. (D) Relative adhension rates at 48 h time point were presented. (E) Lung cancer cells were cultured with DMEM, CAF-CM, CAF-CM + IL-6 neutralizing antibody (5 μg/ml) or DMEM + IL-6 (200 ng/ml) for 24 h. mRNA expression were detected by qPCR. (F) Lung cancer cells were treated with DMEM, CAF-CM, CAF-CM + IL-6 neutralizing antibody (5 μg/ml) or DMEM + IL-6 (200 ng/ml) for 24 h. Protein expression were detected by Western blot. Values represent the mean ± SD from three independent experiments. **P<0.01; ***P<0.001.